The PD-MitoQUANT Project
Today, more than one million people live with Parkinson’s in Europe and this number is forecast to double by 2030. New, more effective treatments are urgently needed – but researchers and companies developing new drugs need to know more about how mitochondrial dysfunction is involved in disease progression and better models are needed for drug discovery and development.
PD-MitoQUANT is an Innovative Medicines Initiative (IMI) project that brings together academic experts, SMEs, pharmaceutical companies from the European Federation of Pharmaceutical Industries and Associations (EFPIA) and patient advocacy organisation Parkinson’s UK to:
improve our understanding of mitochondrial dysfunction in Parkinson’s,
identify and validate molecular drivers and mechanisms in Parkinson’s, and
discover innovative therapeutic targets that can be further progressed by the EFPIA partners in the future.